The Storybook learning library
I want every Storybook family to make informed choices about parasite prevention—not simply choose the most familiar name on the shelf.
My position at Storybook
At Storybook Maltese, I do not recommend NexGard or other isoxazoline flea-and-tick products. My preferred options are Revolution for dogs and Sentinel Flavor Tabs, selected with your veterinarian for your dog’s needs.
Isoxazoline products have been associated with muscle tremors, coordination problems (ataxia), and seizures. Seizures can occur even without a previous history. The FDA also says these products have been used safely in most dogs and cats.
Read the FDA fact sheet →The products I prefer
These are my program preferences, not a claim that either product is risk-free or proven safer than another.
Selamectin · Topical
That tick claim is species-specific. Its dog label does not include intestinal roundworm or hookworm treatment.
Read the Revolution label →Milbemycin oxime + lufenuron · Oral tablet
Does not kill adult fleas. It has no labeled tick protection.
Read the Sentinel Flavor Tabs label →I encourage you to choose a prevention plan with your veterinarian, including appropriate heartworm testing. Both labels report adverse reactions, including neurologic reactions. Don’t combine or switch products on your own.
Be an informed advocate
I encourage families to look at the active ingredients and the parasites a product is labeled to address. Similar names do not mean identical formulas or coverage.
I also ask families to check home remedies with their veterinarian rather than relying on marketing or social-media advice.
If something seems wrong
Contact your veterinarian immediately for tremors, trouble walking, seizures, or another suspected reaction. Seek emergency veterinary care for urgent symptoms. Keep the packaging and lot number, and report the problem to the manufacturer or FDA.
How to report a flea-and-tick product problem →FDA isoxazoline fact sheet · Revolution prescribing information · Sentinel Flavor Tabs prescribing information · FDA reporting guidance
Sources reviewed October 5, 2026.